Early research shows a one-time gene therapy has potential for addressing both the liver and lung disease that patients with ...

KRRO-110 is the first RNA editing development candidate from Korro’s proprietary OPERA TM platform and is currently being evaluated in the Phase 1/2a REWRITE clinical study for AATD. Dosing of the ...

The one-time therapy appears to correct the mutation that causes the disease, known as Alpha-1 antitrypsin deficiency (AATD), ...

Korro Bio’s (KRRO) treatment of alpha-1 antitrypsin deficiency received FDA orphan designation, according to a post on the agency’s stie.Light ...

Korro Bio (NASDAQ:KRRO) said on Friday that it received U.S. FDA's orphan drug designation for investigational medicine ...

Acquired DNA mutations found in the SERPINA1 gene can protect liver cells from damage in patients with alpha-1 antitrypsin ...

BEAM-302 "has set the bar for efficacy in this space," William Blair analysts wrote in an investor note on Monday.

While initial study results suggest Beam's technology can correct alpha-1 antitrypsin deficiency's genetic roots, shares fell ...

BEAM-302 demonstrated safety and efficacy in increasing AAT levels and reducing mutant protein in alpha-1 antitrypsin deficiency patients. Beam Therapeutics announced promising initial results ...

The recent conference, `Alpha 1-antitrypsin deficiency and other conformational diseases', held in Airlie, Virginia, USA (27–30 June, 2000) focused on some of the common pathways by which cells ...

(BEAM), on Monday, announced positive initial data from its Phase 1/2 trial of BEAM-302, a potential treatment for Alpha-1 Antitrypsin Deficiency or AATD, a genetic disorder that affects the lungs ...

Are you searching for effective medications to treat 'Alpha-1 Antitrypsin Deficiency'? This comprehensive guide provides the latest information on medications-both generic and branded-that are ...